ESMO 2020 | ACTIVE trial update: EGFRm NSCLC

Byoung Chul Cho, MD, PhD, Yonsei Cancer Center, Seoul, Korea, discusses updates on the ACTIVE (NCT02824458) multicentered, randomized, double-blind, placebo-controlled phase III trial, comparing the use of apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).